Clinical Trials
8 trialsNCT02195479 2025-08-22
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT03217812 2024-04-25
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Janssen Research & Development, LLC
Phase 3 Completed
NCT02678572 2023-12-21
FOCUS
Delcath Systems Inc.
Phase 3 Completed
NCT05022901 2023-12-21
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
Delcath Systems Inc.
Phase 3 Active not recruiting
NCT00324727 2021-06-21
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
Delcath Systems Inc.
Phase 3 Completed
NCT00689936 2019-11-20
FIRST
Celgene
Phase 3 Completed
NCT01818752 2019-08-26
CLARION
Amgen
Phase 3 Completed
NCT00507416 2014-05-01
UPFRONT
Millennium Pharmaceuticals, Inc.
Phase 3 Completed